Related Experiment Video
Updated: Feb 15, 2026

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 27, 2010
Weighing in on the risks and benefits of probiotic use in HIV-infected and immunocompromised populations
A U Happel1, S L Barnabas1,2, R Froissart3
11 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Medical School, Anzio Road, Observatory, 7925 Cape Town, South Africa.
Insights
Probiotics show benefits outweighing risks for HIV patients and neonates with colic or necrotising enterocolitis (NEC). Careful use is advised for immunocompromised individuals and the elderly.
Area of Science:
- Microbiology
- Immunology
- Gastroenterology
Background:
- Probiotics are widely used for various conditions like irritable bowel syndrome, diarrhea, necrotising enterocolitis (NEC), and infant colic.
- Significant debate exists regarding probiotic efficacy and safety, especially in HIV-infected and immunocompromised populations.
Purpose of the Study:
- To review safety and adverse event (AE) reporting from clinical trials of probiotics in at-risk populations.
- To evaluate the risk-benefit profile of probiotics in vulnerable groups.
Main Methods:
- Systematic review of clinical trial data focusing on safety and AE reporting.
- Analysis of studies involving HIV-infected individuals, the terminally ill, the elderly, and neonates.
Main Results:
- Probiotic therapy benefits appear to outweigh risks in HIV-infected populations.
- Probiotics are beneficial for treating colic and NEC in low birth weight or premature neonates.
- Severe AEs were predominantly reported in the elderly, terminally ill, or those with severe co-existing medical conditions.
Conclusions:
- Probiotic use as adjunctive therapy is effective and safe for most patients, including HIV-infected individuals.
- Caution is warranted for individuals with extreme immunosuppression and severe medical conditions across all age groups.
Abstract:
Probiotics are used in the prophylaxis and treatment of several conditions, including irritable bowel syndrome, diarrhoea, necrotising enterocolitis (NEC) and colic in infants. Despite the long history of probiotic use in humans, there is still significant debate about their efficacy and safety, particularly in HIV-infected and immunocompromised individuals. Here, we reviewed the safety and adverse event (AE) reporting from clinical trials that have tested probiotics in at risk populations, including HIV-infected individuals, the terminally ill and elderly, and neonates. Our analysis suggests that the benefits of probiotic therapy outweigh their potential risks in HIV-infected populations, and in the treatment of colic and NEC in low birth weight or premature neonates. Most case reports of severe AEs were in the elderly and terminally ill, or in those with additional severe medical conditions. We conclude that probiotic use, as adjunctive treatment, is effective and safe in the majority of patients including HIV-infected individuals, although special care should be taken in individuals with extreme immunosuppression and severe medical conditions in all ages.
More Related Videos
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Conservation of Small Populations
Benefits of Self-Esteem
What is Population Genetics?
Population Growth
Relative Risk

